AnteoTech Limited (ADO.AX)
AUD 0.01
(-7.14%)
AUD 0.01
(-7.14%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 | 460.39 Thousand AUD | 25.89% |
| 2023 | 365.72 Thousand AUD | -51.93% |
| 2022 | 760.87 Thousand AUD | -15.28% |
| 2021 | 898.06 Thousand AUD | -29.06% |
| 2020 | 1.26 Million AUD | 358.16% |
| 2019 | 276.31 Thousand AUD | -71.84% |
| 2018 | 981.31 Thousand AUD | -60.3% |
| 2017 | 2.47 Million AUD | 164.88% |
| 2016 | -3.8 Million AUD | -912.61% |
| 2015 | 468.78 Thousand AUD | 51.34% |
| 2014 | 309.75 Thousand AUD | -39.3% |
| 2013 | 510.29 Thousand AUD | 25.94% |
| 2012 | 405.17 Thousand AUD | 92.88% |
| 2011 | 210.06 Thousand AUD | -20.96% |
| 2010 | 265.75 Thousand AUD | -60.61% |
| 2009 | 674.61 Thousand AUD | -40.59% |
| 2008 | 1.13 Million AUD | -38.84% |
| 2007 | 1.85 Million AUD | 129.33% |
| 2006 | 809.6 Thousand AUD | 90.72% |
| 2005 | 424.5 Thousand AUD | -67.8% |
| 2004 | 1.31 Million AUD | 111.98% |
| 2003 | 622 Thousand AUD | 32.06% |
| 2002 | 471 Thousand AUD | 0.0% |
| 2001 | - AUD | 0.0% |
| 2000 | - AUD | 0.0% |
| 1999 | - AUD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q4 | -3.69 Million AUD | 0.0% |
| 2024 FY | 460.39 Thousand AUD | 25.89% |
| 2024 Q2 | 346 Thousand AUD | 0.0% |
| 2023 Q2 | 3.51 Million AUD | 0.0% |
| 2023 FY | 365.72 Thousand AUD | -51.93% |
| 2023 Q4 | 77.94 Thousand AUD | 0.0% |
| 2022 FY | 760.87 Thousand AUD | -15.28% |
| 2022 Q4 | 392.4 Thousand AUD | 0.0% |
| 2022 Q2 | 2.33 Million AUD | 0.0% |
| 2021 FY | 898.06 Thousand AUD | -29.06% |
| 2021 Q2 | 1.74 Million AUD | 0.0% |
| 2021 Q4 | 352.48 Thousand AUD | 0.0% |
| 2020 Q4 | 208.99 Thousand AUD | 0.0% |
| 2020 FY | 1.26 Million AUD | 358.16% |
| 2020 Q2 | 1.05 Million AUD | 0.0% |
| 2019 FY | 276.31 Thousand AUD | -71.84% |
| 2019 Q2 | 209.41 Thousand AUD | 0.0% |
| 2019 Q4 | 66.9 Thousand AUD | 0.0% |
| 2018 Q4 | - AUD | 0.0% |
| 2018 Q2 | 140.17 Thousand AUD | 0.0% |
| 2018 FY | 981.31 Thousand AUD | -60.3% |
| 2017 Q4 | - AUD | 0.0% |
| 2017 FY | 2.47 Million AUD | 164.88% |
| 2017 Q2 | 2.22 Million AUD | 0.0% |
| 2016 Q4 | - AUD | 0.0% |
| 2016 Q2 | 590.98 Thousand AUD | 0.0% |
| 2016 FY | -3.8 Million AUD | -912.61% |
| 2015 FY | 468.78 Thousand AUD | 51.34% |
| 2015 Q4 | 468.78 Thousand AUD | 0.0% |
| 2015 Q2 | - AUD | 0.0% |
| 2014 Q2 | - AUD | 0.0% |
| 2014 Q4 | 309.75 Thousand AUD | 0.0% |
| 2014 FY | 309.75 Thousand AUD | -39.3% |
| 2013 Q2 | 127.57 Thousand AUD | 25.94% |
| 2013 Q1 | 101.29 Thousand AUD | 0.0% |
| 2013 FY | 510.29 Thousand AUD | 25.94% |
| 2013 Q4 | 219.56 Thousand AUD | 72.11% |
| 2013 Q3 | 127.57 Thousand AUD | 0.0% |
| 2012 Q4 | - AUD | -100.0% |
| 2012 Q2 | 101.29 Thousand AUD | 92.88% |
| 2012 Q1 | 52.51 Thousand AUD | 0.0% |
| 2012 FY | 405.17 Thousand AUD | 92.88% |
| 2012 Q3 | 101.29 Thousand AUD | 0.0% |
| 2011 Q3 | 52.51 Thousand AUD | 0.0% |
| 2011 FY | 210.06 Thousand AUD | -20.96% |
| 2011 Q2 | 52.51 Thousand AUD | -20.96% |
| 2011 Q1 | 66.43 Thousand AUD | 0.0% |
| 2011 Q4 | - AUD | -100.0% |
| 2010 Q2 | 66.43 Thousand AUD | 17.43% |
| 2010 Q3 | 66.43 Thousand AUD | 0.0% |
| 2010 FY | 265.75 Thousand AUD | -60.61% |
| 2010 Q4 | - AUD | -100.0% |
| 2010 Q1 | 56.57 Thousand AUD | 0.0% |
| 2009 Q2 | 56.57 Thousand AUD | 179.01% |
| 2009 Q3 | 56.57 Thousand AUD | 0.0% |
| 2009 Q4 | - AUD | -100.0% |
| 2009 Q1 | 20.27 Thousand AUD | 0.0% |
| 2009 FY | 674.61 Thousand AUD | -40.59% |
| 2008 Q3 | 20.27 Thousand AUD | 0.0% |
| 2008 Q1 | 22.78 Thousand AUD | 0.0% |
| 2008 FY | 1.13 Million AUD | -38.84% |
| 2008 Q4 | - AUD | -100.0% |
| 2008 Q2 | 20.27 Thousand AUD | -11.0% |
| 2007 FY | 1.85 Million AUD | 129.33% |
| 2007 Q4 | - AUD | -100.0% |
| 2007 Q2 | 22.78 Thousand AUD | -88.74% |
| 2007 Q1 | 202.4 Thousand AUD | 0.0% |
| 2007 Q3 | 22.78 Thousand AUD | 0.0% |
| 2006 FY | 809.6 Thousand AUD | 90.72% |
| 2006 Q2 | 202.4 Thousand AUD | 90.72% |
| 2006 Q3 | 202.4 Thousand AUD | 0.0% |
| 2006 Q1 | 106.12 Thousand AUD | 0.0% |
| 2006 Q4 | - AUD | -100.0% |
| 2005 Q3 | 106.12 Thousand AUD | 0.0% |
| 2005 Q1 | 304.29 Thousand AUD | 0.0% |
| 2005 Q4 | - AUD | -100.0% |
| 2005 Q2 | 106.12 Thousand AUD | -65.12% |
| 2005 FY | 424.5 Thousand AUD | -67.8% |
| 2004 Q3 | 304.29 Thousand AUD | 0.0% |
| 2004 Q4 | - AUD | -100.0% |
| 2004 FY | 1.31 Million AUD | 111.98% |
| 2004 Q1 | 183.5 Thousand AUD | 0.0% |
| 2004 Q2 | 304.29 Thousand AUD | 65.82% |
| 2003 Q4 | - AUD | -100.0% |
| 2003 Q1 | -27.68 Thousand AUD | 0.0% |
| 2003 Q3 | 183.5 Thousand AUD | 0.0% |
| 2003 Q2 | 183.5 Thousand AUD | 762.78% |
| 2003 FY | 622 Thousand AUD | 32.06% |
| 2002 Q1 | - AUD | 0.0% |
| 2002 Q2 | -27.68 Thousand AUD | 0.0% |
| 2002 FY | 471 Thousand AUD | 0.0% |
| 2002 Q3 | -27.68 Thousand AUD | 0.0% |
| 2002 Q4 | - AUD | 100.0% |
| 2001 Q2 | - AUD | 0.0% |
| 2001 FY | - AUD | 0.0% |
| 2001 Q4 | - AUD | 0.0% |
| 2001 Q3 | - AUD | 0.0% |
| 2001 Q1 | - AUD | 0.0% |
| 2000 Q1 | - AUD | 0.0% |
| 2000 Q2 | - AUD | 0.0% |
| 2000 Q3 | - AUD | 0.0% |
| 2000 Q4 | - AUD | 0.0% |
| 2000 FY | - AUD | 0.0% |
| 1999 Q3 | - AUD | 0.0% |
| 1999 FY | - AUD | 0.0% |
| 1999 Q4 | - AUD | 0.0% |
| 1999 Q2 | - AUD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Memphasys Limited | 1606.00 AUD | -28567.31% |
| Race Oncology Limited | 1.38 Million AUD | 66.876% |
| AdAlta Limited | 1.5 Million AUD | 69.468% |
| Anatara Lifesciences Ltd | -748.91 Thousand AUD | 161.476% |
| Bio-Gene Technology Limited | -301.44 Thousand AUD | 252.728% |
| BTC Health Limited | 16.36 Thousand AUD | -2714.163% |
| CSL Limited | 15.28 Billion AUD | 99.997% |
| Clarity Pharmaceuticals Ltd | 11.5 Million AUD | 95.999% |
| Cynata Therapeutics Limited | 2.31 Million AUD | 80.118% |
| Imugene Limited | -5.83 Million AUD | 107.884% |
| NeuroScientific Biopharmaceuticals Limited | -91.33 Thousand AUD | 604.064% |
| PharmAust Limited | -1641.00 AUD | 28155.881% |
| Proteomics International Laboratories Limited | -1.12 Million AUD | 140.99% |
| Acrux Limited | -1.28 Million AUD | 135.856% |
| Botanix Pharmaceuticals Limited | -6.55 Million AUD | 107.027% |
| Clinuvel Pharmaceuticals Limited | 78.09 Million AUD | 99.41% |
| Island Pharmaceuticals Limited | 1.25 Million AUD | 63.215% |
| Nyrada Inc. | -5164.07 AUD | 9015.39% |
| Orthocell Limited | 3.68 Million AUD | 87.518% |
| Radiopharm Theranostics Limited | -21.3 Million AUD | 102.161% |
| Starpharma Holdings Limited | 7.65 Million AUD | 93.987% |
| Zelira Therapeutics Limited | 10.28 Thousand AUD | -4376.828% |
| Arovella Therapeutics Limited | -25.97 Thousand AUD | 1872.189% |
| Alterity Therapeutics Limited | 3.8 Million AUD | 87.9% |
| Amplia Therapeutics Limited | 4.01 Million AUD | 88.521% |
| Biome Australia Limited | 7.66 Million AUD | 93.997% |
| Biotron Limited | -40.49 Thousand AUD | 1236.839% |
| Chimeric Therapeutics Limited | 7.45 Million AUD | 93.823% |
| EZZ Life Science Holdings Limited | 50.94 Million AUD | 99.096% |
| Immutep Limited | 1.44 Million AUD | 68.114% |
| Invex Therapeutics Ltd | 1.21 Million AUD | 62.021% |
| Noxopharm Limited | -534.81 Thousand AUD | 186.086% |
| Patrys Limited | 1.39 Million AUD | 66.977% |
| Prescient Therapeutics Limited | 3.71 Million AUD | 87.598% |
| PYC Therapeutics Limited | 22.05 Million AUD | 97.913% |
| Telix Pharmaceuticals Limited | 308.5 Million AUD | 99.851% |
| Dimerix Limited | 583.47 Thousand AUD | 21.094% |
| Hexima Limited | - AUD | -Infinity% |
| Neuren Pharmaceuticals Limited | 205.17 Million AUD | 99.776% |
| Nanollose Limited | -348.95 Thousand AUD | 231.937% |
| Tissue Repair Ltd | 150.51 Thousand AUD | -205.889% |
| Paradigm Biopharmaceuticals Limited | 56.81 Thousand AUD | -710.387% |
| Recce Pharmaceuticals Ltd | -366.76 Thousand AUD | 225.528% |
| Avecho Biotechnology Limited | -43.79 Thousand AUD | 1151.255% |
| Actinogen Medical Limited | 9.93 Million AUD | 95.364% |
| Immuron Limited | 3.33 Million AUD | 86.202% |
| Argenica Therapeutics Limited | 2.59 Million AUD | 82.278% |